PMV Pharmaceuticals, Inc.
PMVP
Rank in Stocks
#21499
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on... PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Share Price
$1.25
Last synced: 2026-11-09
Market Cap
$66.66M
Change (1 day)
-0.79%
Change (1 year)
-6.02%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade PMV Pharmaceuticals, Inc. (PMVP)
Category
Healthcare
EPS for PMV Pharmaceuticals, Inc. (PMVP)
EPS as of June 2026 TTM: $-1.42
According to PMV Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-1.42. At the end of 2025 the company had an EPS of $-1.48, a decrease compared to its 2024 EPS of $-1.14.
EPS history for PMV Pharmaceuticals, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.42 | -4.05% |
| 2025 | $-1.48 | 30.03% |
| 2024 | $-1.14 | -20.96% |
| 2023 | $-1.44 | -10.56% |
| 2022 | $-1.61 | 25.78% |
| 2021 | $-1.28 | -46.67% |
| 2020 | $-2.40 | 306.78% |
| 2019 | $-0.59 | -89.83% |
| 2018 | $-5.80 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,202.82% |
US
|
|
| $-7.07 | 397.89% |
US
|
|
| $-5.29 | 272.54% |
AU
|
|
| $12.88 | -1,007.05% |
BE
|
|
| $21.56 | -1,618.31% |
NL
|
Questions about PMV Pharmaceuticals, Inc.'s earnings per share (EPS)
What is PMV Pharmaceuticals, Inc.'s earnings per share (EPS)?
PMV Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-1.42, as of Jun 2026.
What was PMV Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, PMV Pharmaceuticals, Inc.'s earnings per share (EPS) was $-1.48, compared with $-1.14 in 2024.
How has PMV Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, PMV Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.14) and lowest in 2020 ($-2.40).
How does PMV Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
PMV Pharmaceuticals, Inc.'s earnings per share (EPS) ($-1.42) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.